Home > Publications > Disease Control Priorities in Developing Countries >

6. Product Development Priorities

Table 6.4: Product Development PPPs' Portfolios, 2004

Product Development PPPs' Portfolios, 2004
	Number of products in
PPP	Preclinical trials	Phase 1	Phase 2	Phase 3
Aeras		2
Drugs for Neglected Diseases Initiative^a				3
European Malaria Vaccine Initiative
Foundation for Innovative New Diagnostics		1	1	1
GATB^b	10	0	1	0
Human Hookworm Vaccine Initiative	2
International AIDS Vaccine Initiative	2	2	1
Institute for One World Health	3		1	1
International Partnership for Microbicides
Microbicides Development Programme		1		1
MMV	14 in discovery	4	2	2
Malaria Vaccine Initiative	8	6	1
Pediatric Dengue Vaccine Initiative
South African AIDS Vaccine Initiative^c	6	0
Total	47	16	7	8
Of which drugs	26	8	5	8
Of which vaccines	19	8	2	0

Sources: Initiative on Public-Private Partnerships for Health survey, PPPs' Web sites, interviews.

a. The Drugs for Neglected Diseases Initiative has two malaria drugs in phase 3 that are partly financed by the European Union.

b. The GATB anticipates a portfolio of three phase 1 trials and expects its current phase 2 trial will enter phase 3 before 2007. Its portfolio also includes platform-related investments.

c. The South African AIDS Vaccine Initiative does not yet have any of its own products at phase 1 but is collaborating on two projects that are at this stage.

< Back to Chapter Summary Page

6. Product Development Priorities

Table 6.4: Product Development PPPs' Portfolios, 2004

Chapter Sections

Tables